{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:37:12Z","timestamp":1792521432250,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T00:00:00Z","timestamp":1549497600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12887-019-1425-7","type":"journal-article","created":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T09:04:01Z","timestamp":1549530241000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study"],"prefix":"10.1186","volume":"19","author":[{"given":"Saul N.","family":"Faust","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maguelone","family":"Le Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitsanu","family":"Pancharoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel Rodriguez","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Cathie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Behre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Bernatoniene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Snape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Helm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Eduardo","family":"Medina Pech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ouzama","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Baccarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Povey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Gillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,7]]},"reference":[{"key":"1425_CR1","first-page":"265","volume":"89","author":"Varicella and herpes zoster vaccines","year":"2014","unstructured":"Varicella and herpes zoster vaccines. WHO position paper, June 2014. Wkly Epidemiol Rec. 2014;89:265\u201387.","journal-title":"Wkly Epidemiol Rec"},{"key":"1425_CR2","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1080\/14760584.2017.1343669","volume":"16","author":"P Wutzler","year":"2017","unstructured":"Wutzler P, Bonanni P, Burgess M, Gershon A, Safadi MA, Casabona G. Varicella vaccination - the global experience. Expert Rev Vaccines. 2017;16:833\u201343.","journal-title":"Expert Rev Vaccines"},{"key":"1425_CR3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.2165\/0063030-200822060-00005","volume":"22","author":"HW Kreth","year":"2008","unstructured":"Kreth HW, Lee BW, Kosuwon P, Salazar J, Gloriani-Barzaga N, Bock HL, Meurice F. Sixteen years of global experience with the first refrigerator-stable varicella vaccine (Varilrix). BioDrugs. 2008;22:387\u2013402.","journal-title":"BioDrugs"},{"key":"1425_CR4","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1586\/14760584.4.5.629","volume":"4","author":"SS Chiu","year":"2005","unstructured":"Chiu SS, Lau YL. Review of the Varilrix varicella vaccine. Expert Rev Vaccines. 2005;4:629\u201343.","journal-title":"Expert Rev Vaccines."},{"key":"1425_CR5","unstructured":"The European Agency for the Evaluation of Medicinal Products: Note for guidance on plasma-derived medicinal products. 2001. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003613.pdf\n                    \n                  . Accessed 14 Aug 2018."},{"key":"1425_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12887-016-0546-5","volume":"16","author":"R Prymula","year":"2016","unstructured":"Prymula R, Simko R, Povey M, Kulcsar A. Varicella vaccine without human serum albumin versus licensed varicella vaccine in children during the second year of life: a randomized, double-blind, non-inferiority trial. BMC Pediatr. 2016;16:7.","journal-title":"BMC Pediatr"},{"key":"1425_CR7","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1016\/j.vaccine.2004.01.016","volume":"22","author":"J Bonhoeffer","year":"2004","unstructured":"Bonhoeffer J, Kohl K, Chen R, Duclos P, Heijbel H, Heininger U, Jefferson T, Loupi E. The Brighton collaboration-enhancing vaccine safety. Vaccine. 2004;22:2046.","journal-title":"Vaccine"},{"key":"1425_CR8","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1542\/peds.2008-0939","volume":"121","author":"Steering Committee on Quality Improvement and Management","year":"2008","unstructured":"Steering Committee on Quality Improvement and Management. Subcommittee on Febrile Seizures American Academy of Pediatrics. Febrile seizures: clinical practice guideline for the long-term management of the child with simple febrile seizures. Pediatrics. 2008;121:1281\u20136.","journal-title":"Pediatrics"},{"key":"1425_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3390\/children4090081","volume":"4","author":"E Barbi","year":"2017","unstructured":"Barbi E, Marzuillo P, Neri E, Naviglio S, Krauss BS. Fever in children: pearls and pitfalls. Child Aust. 2017;4:81.","journal-title":"Child Aust"},{"key":"1425_CR10","unstructured":"Varilrix. Summary of produc characteristics. Last updated 12 Sept 2018. \n                    https:\/\/www.medicines.org.uk\/emc\/product\/1676\/smpc\n                    \n                  . Accessed 14 Aug 2018."},{"key":"1425_CR11","unstructured":"World Health Organization. Information sheet. Observed rate of vaccine reactions Varicella zoster virus vaccines 2012 \n                    http:\/\/www.who.int\/vaccine_safety\/initiative\/tools\/Varicella_Zoster_Vaccine_rates_information_sheet.pdf\n                    \n                  . Accessed 4 Oct 2018."},{"key":"1425_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1136\/adc.85.2.83","volume":"85","author":"SA Skull","year":"2001","unstructured":"Skull SA, Wang EE. Varicella vaccination-a critical review of the evidence. Arch Dis Child. 2001;85:83\u201390.","journal-title":"Arch Dis Child"},{"key":"1425_CR13","first-page":"38","volume":"39","author":"MY Lu","year":"1998","unstructured":"Lu MY, Huang LM, Lee CY, Lee PI, Chiu HH, Tsai HY. Evaluation of a live attenuated varicella vaccine in 15- to 18-month-old healthy children. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1998;39:38\u201342.","journal-title":"Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi"},{"key":"1425_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1155\/2000\/647245","volume":"11","author":"F Diaz-Mitoma","year":"2000","unstructured":"Diaz-Mitoma F, Halperin SA, Scheifele D. Reactogenicity to a live attenuated varicella vaccine in Canadian children. Can J Infect Dis. 2000;11:97\u2013101.","journal-title":"Can J Infect Dis"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-019-1425-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12887-019-1425-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-019-1425-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:10:11Z","timestamp":1581034211000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-019-1425-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,7]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1425"],"URL":"https:\/\/doi.org\/10.1186\/s12887-019-1425-7","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,7]]},"assertion":[{"value":"24 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by independent ethics committees\/institutional review boards at each site (University of Tartu, Office of Research and Development; Landesarztekammer Baden-Wurttemberg Medical Board; National Institute of Pediatrics, Coyoacan; Medical Care and Research, Merida; Faculty of Medicine, Chulalongkorn University; NHS, Health Research Authority, North West-Liverpool East Research Ethics Committee) and conducted in accordance with provisions of the Declaration of Helsinki. Written informed consent was obtained from all children\u2019s parents prior to enrolment in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MLR, OH, CB, MP and PG are employees of the GSK group of companies, and OH and PG hold shares in the GSK group of companies as part of their employee remuneration. CB was employed by the GSK group of companies during the conduct of this study and is a current employee of Sanofi Pasteur. She holds shares in the GSK group of companies and Sanofi Pasteur. SNF declares that his institution received grants from the GSK group of companies for the conduct of this trial. SNF also declares support through his institution for the conduct of other trials (from the GSK group of companies, Sanofi-Pasteur, Pfizer, AstraZeneca, MedImmune, Alios, Ablynx and Merck). SNF declares that his institution received other support from Pfizer, AstraZeneca, MedImmune, Sanofi, Sequerius and Merck for advisory board participation. MDS declares that his institution received grants from the GSK group of companies for the conduct of this trial. MDS also declares support through his institution for the conduct of other trials (from the GSK group of companies, Sanofi-Pasteur, Pfizer, MedImmune, Novavax and Johnson and Johnson). CP, MA RW, KC, UB, JB, KH and CE MP have indicated they have no financial relationship or conflict of interest relevant to this article to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"50"}}